Oncology Central

ESMO WCGI: Adjuvant FOLFIRINOX new standard of care for pancreatic cancer

0
Adjuvant FOLFIRINOX chemotherapy has become the standard of care for pancreatic cancer patients following the release of data from the Phase III PRODIGE 24/CCTG PA.6 trial.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.